Search clinical trials for: BMS-986315

Total 1989 results

Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States, Argentina, Canada, France, Greece, Italy, Netherlands, United Kingdom
Biotronik France
MedPass International

Unknown

PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon (PaneLux PTCA)

Coronary Artery Disease | High Bleeding Risk Patients

France
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Mexico, Australia, Colombia, Chile, Peru
Bristol-Myers Squibb

Completed

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

Ulcerative Colitis

United States
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Healthy Volunteers

United States
University Health Network, Toronto

Completed

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Basal Cell Nevus Syndrome

Canada
The University of Hong Kong

Not yet recruiting

Integrative Body-Mind-Spirit Group Intervention for Infertile Couples

Infertility

Hong Kong
Bristol-Myers Squibb

Terminated

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Alopecia Areata

Canada, France, Japan, Australia, United States, Poland
Memorial Sloan Kettering Cancer Center
BMS Foundation

Recruiting

Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery

Peripheral Arterial Disease (PAD) in Cancer Patients

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Healthy Participants

China
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
Bristol-Myers Squibb

Terminated

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Diabetic Kidney Disease

United States, Canada, Denmark, France
Bristol-Myers Squibb

Terminated

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Advanced Cancer

Chile, United States, Argentina, Australia, Belgium, Canada, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Romania, Spain, Switzerland
Catharina Ziekenhuis Eindhoven
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Compusense... and other collaborators

Completed

Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction (DEBATER)

Acute Myocardial Infarction

Netherlands
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Biogen

Completed

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Tauopathies

United States
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Bristol-Myers Squibb

Completed

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Healthy Participants

United States
Massachusetts General Hospital
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Dasatinib in Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Svelte Medical Systems Europe

Terminated

Acrobat Coronary Stent System Effectiveness European Study (ACES)

Coronary Artery Disease

Spain, France, Belgium
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Dan Zandberg
Bristol-Myers Squibb

Active, not recruiting

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Squamous Cell Carcinoma of the Head and Neck

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States, United Kingdom
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Gastric Cancer

China, Japan, Korea, Republic of, Taiwan
China National Center for Cardiovascular Diseases
Peking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...

Unknown

A New Classification and Interventional Therapy for Coronary Artery Ectasia (NCIPCAE)

Coronary Artery Ectasia

China
Bristol-Myers Squibb

Completed

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Systemic Lupus Erythematosus | Inflammatory Bowel Diseases | Psoriasis | Arthritic Psoriasis

United States
Bristol-Myers Squibb

Completed

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

Healthy Participants

United States
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Italy, Australia, Poland, Spain
Taipei City Hospital

Completed

Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques (MV:main branch)

Stable Angina

Taiwan
Stentys

Terminated

Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V)

Acute Myocardial Infarction

Netherlands, United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

Healthy Participants

Germany
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

Healthy Participants

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Healthy Volunteers

United Kingdom
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

United States, France, Spain, Germany
Bristol-Myers Squibb

Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

Cancer

Switzerland
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

Heart Failure With Reduced Ejection Fraction

United States

3

Subscribe